TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela purchased 34,328 shares of the stock in a transaction on Wednesday, November 18th. The shares were bought at an average cost of $2.59 per share, for a total transaction of $88,909.52. Following the transaction, the chief executive officer directly owned 1,140,182 shares in the company, valued at approximately $2,953,071.38. The trade was a 3.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
TriSalus Life Sciences Stock Down 11.4%
Shares of NASDAQ TLSI traded down $0.28 during trading hours on Thursday, hitting $2.17. The company had a trading volume of 364,646 shares, compared to its average volume of 302,213. The stock has a market capitalization of $133.62 million, a P/E ratio of -4.43 and a beta of 0.50. The company has a quick ratio of 3.86, a current ratio of 4.22 and a debt-to-equity ratio of 47.60. TriSalus Life Sciences, Inc. has a 1-year low of $2.16 and a 1-year high of $7.95. The firm's 50 day moving average is $3.90 and its 200-day moving average is $4.26.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million. On average, analysts expect that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current fiscal year.
Analysts Set New Price Targets
TLSI has been the subject of several recent analyst reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. Canaccord Genuity Group lowered their price target on TriSalus Life Sciences from $7.00 to $4.00 and set a "buy" rating on the stock in a research report on Tuesday, November 10th. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Finally, Zacks Research upgraded TriSalus Life Sciences to a "hold" rating in a research note on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.20.
Check Out Our Latest Report on TLSI
Hedge Funds Weigh In On TriSalus Life Sciences
A number of large investors have recently made changes to their positions in TLSI. State Street Corp boosted its stake in shares of TriSalus Life Sciences by 86.3% in the second quarter. State Street Corp now owns 610,963 shares of the company's stock valued at $2,780,000 after buying an additional 282,943 shares during the period. BlackRock Inc. acquired a new position in TriSalus Life Sciences during the 2nd quarter worth approximately $12,099,000. Nantahala Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $4,550,000. First Light Asset Management LLC raised its holdings in TriSalus Life Sciences by 29.3% in the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company's stock valued at $29,814,000 after buying an additional 1,485,664 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of TriSalus Life Sciences during the second quarter worth $507,000. Institutional investors own 2.58% of the company's stock.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company's TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.